"immunoactivity" meaning in All languages combined

{
  "etymology_templates": [
    {
      "args": {
        "1": "en",
        "2": "immuno",
        "3": "activity"
      },
      "expansion": "immuno- + activity",
      "name": "prefix"
    }
  ],
  "etymology_text": "From immuno- + activity.",
  "forms": [
    {
      "form": "immunoactivities",
      "tags": [
        "plural"
      ]
    }
  ],
  "head_templates": [
    {
      "args": {
        "1": "-",
        "2": "+"
      },
      "expansion": "immunoactivity (usually uncountable, plural immunoactivities)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [
            "Entries with incorrect language header",
            "Entry maintenance"
          ],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "English terms prefixed with immuno-",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with 1 entry",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with entries",
          "parents": [],
          "source": "w"
        }
      ],
      "examples": [
        {
          "ref": "2015 July 2, Ho-Chul Kim et al., “Combined effect of bisphosphonate and recombinant human bone morphogenetic protein 2 on bone healing of rat calvarial defects”, in Maxillofacial Plastic and Reconstructive Surgery, volume 37, →DOI:",
          "text": "Magnification X 100 Immunohistochemistry analysis of collagen type I, OPG and RANKL (−; no immunoreactivity, +; weak immunoactivity, ++; moderate immunoactivity, +++; strong immunoactivity, Abbreviations: OPG osteoprotegerin, RANKL receptor activator nuclear factor κB ligand) In the analysis of OPG expression, it shows moderate expression at 2, 4 weeks, and decrease at 8 weeks.",
          "type": "quote"
        }
      ],
      "glosses": [
        "The quality or degree of being immunoactive."
      ],
      "id": "en-immunoactivity-en-noun-fDLfywhl",
      "links": [
        [
          "immunoactive",
          "immunoactive"
        ]
      ],
      "tags": [
        "uncountable",
        "usually"
      ]
    }
  ],
  "word": "immunoactivity"
}

{
  "etymology_templates": [
    {
      "args": {
        "1": "en",
        "2": "immuno",
        "3": "activity"
      },
      "expansion": "immuno- + activity",
      "name": "prefix"
    }
  ],
  "etymology_text": "From immuno- + activity.",
  "forms": [
    {
      "form": "immunoactivities",
      "tags": [
        "plural"
      ]
    }
  ],
  "head_templates": [
    {
      "args": {
        "1": "-",
        "2": "+"
      },
      "expansion": "immunoactivity (usually uncountable, plural immunoactivities)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        "English countable nouns",
        "English entries with incorrect language header",
        "English lemmas",
        "English nouns",
        "English terms prefixed with immuno-",
        "English terms with quotations",
        "English uncountable nouns",
        "Pages with 1 entry",
        "Pages with entries"
      ],
      "examples": [
        {
          "ref": "2015 July 2, Ho-Chul Kim et al., “Combined effect of bisphosphonate and recombinant human bone morphogenetic protein 2 on bone healing of rat calvarial defects”, in Maxillofacial Plastic and Reconstructive Surgery, volume 37, →DOI:",
          "text": "Magnification X 100 Immunohistochemistry analysis of collagen type I, OPG and RANKL (−; no immunoreactivity, +; weak immunoactivity, ++; moderate immunoactivity, +++; strong immunoactivity, Abbreviations: OPG osteoprotegerin, RANKL receptor activator nuclear factor κB ligand) In the analysis of OPG expression, it shows moderate expression at 2, 4 weeks, and decrease at 8 weeks.",
          "type": "quote"
        }
      ],
      "glosses": [
        "The quality or degree of being immunoactive."
      ],
      "links": [
        [
          "immunoactive",
          "immunoactive"
        ]
      ],
      "tags": [
        "uncountable",
        "usually"
      ]
    }
  ],
  "word": "immunoactivity"
}